Michael Tomac

Michael Tomac has worked in a variety of roles since 2008. Michael began their career as an Undergraduate Researcher at Chapman University, where they investigated the effect of resistance training on the bone mineral density of Sprague Dawley rats. Michael then moved on to a Student Tutor role at the same institution. In 2010, they worked as an AmeriCorps Member, providing services for a low-income rural community. Later that same year, they worked as a Regulatory Specialist for the Florida Department of Health. In 2011, they worked as a Chapter Representative for GreekBill, managing the accounts of over 100 clients. From 2015 to 2016, they worked as a QC Process Control Associate II at B. Braun Medical and as a Graduate Research Assistant at Chapman University, respectively. In 2017, they were a Research and Development Intern at Zymo Research Corp. From 2018 to 2019, they worked as an Associate Scientist at the University of New Mexico Health Sciences Center, where they worked on elucidating the mechanisms of damage in Intracerebral Hemorrhage using a rat model and developing a gene therapy for Myotonic Dystrophy Type I (DM1) using CRISPR/Cas9 in an AAV vector. Most recently, they have been an Application Scientist at Indica Labs since 2019.

Michael Tomac completed their Bachelor of Science in Biology, General from Chapman University in 2009. Michael then returned to Chapman University in 2016 and earned their Master of Science in Pharmaceutical Sciences in 2018.